MIG
NTLA icon

McGuire Investment Group’s Intellia Therapeutics NTLA Stock Holding History

McGuire Investment Group’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-71,301
Closed -$1.47M – 117
2024
Q3 		$1.47M Sell
71,301
-693
-1% -$16K 0.21% 63
2024
Q2 		$1.61M Sell
71,994
-4,498
-6% -$107K 0.23% 59
2024
Q1 		$2.1M Buy
76,492
+25,983
+51% +$722K 0.31% 59
2023
Q4 		$1.54M Sell
50,509
-15,475
-23% -$445K 0.26% 58
2023
Q3 		$2.09M Buy
65,984
+2,550
+4% +$98.9K 0.4% 53
2023
Q2 		$2.59M Buy
63,434
+11,021
+21% +$447K 0.48% 50
2023
Q1 		$1.95M Buy
52,413
+17,332
+49% +$680K 0.39% 51
2022
Q4 		$1.22M Buy
+35,081
New +$1.67M 0.26% 57

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

McGuire Investment Group's NTLA Position: Q4 2024 in Review

McGuire Investment Group sold out of Intellia Therapeutics (NTLA) in Q4 2024, closing a stake of 71,301 shares — an estimated $1.47M sold.

McGuire Investment Group first reported a position in NTLA in Q4 2022 and held it in 8 quarters. The position peaked at $2.59M in Q2 2023. 294 funds tracked by Wall St. Rank hold NTLA as of Q4 2024.

  • McGuire Investment Group reported no remaining Intellia Therapeutics position as of Q4 2024 after selling out during the quarter.
  • McGuire Investment Group sold 71,301 Intellia Therapeutics shares in Q4 2024, an estimated $1.47M.
  • McGuire Investment Group first reported a position in Intellia Therapeutics in Q4 2022 and held it in 8 quarters.
  • McGuire Investment Group's Intellia Therapeutics position peaked at $2.59M in Q2 2023.
  • 294 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2024.

Based on McGuire Investment Group's 13F filing for Q4 2024, filed 21 Jan 2025.